everolimus < every < everyday

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by every

Number of relevant bibliographic references: 152.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000034 (2020)	Angelika Batta ; Bhupinder Singh Kalra ; Raj Khirasaria	Trends in FDA drug approvals over last 2 decades: An observational study
000075 (2020)	Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]	Thoughts on COVID-19 and autoimmune diseases
000353 (2020)	Tian-Yu Lin ; Yu-Hsiang Hsu [Taïwan]	IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target
000397 (2020)	Andrei A. Deviatkin ; Yulia A. Vakulenko [Russie] ; Ludmila V. Akhmadishina ; Vadim V. Tarasov ; Marina I. Beloukhova ; Andrey A. Zamyatnin Jr. [Russie] ; Alexander N. Lukashev	Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
000403 (2020)	Hiroki Hoshino [Japon] ; Yoko Shirai [Japon] ; Hiroe Konishi [Japon] ; Takashi Yamamura [Japon] ; Norikazu Shimizu [Japon]	Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: A 12-year-old boy.
000406 (2020)	Maurizio Benucci [Italie] ; Luciana Tramacere [Italie] ; Maria Infantino [Italie] ; Mariangela Manfredi [Italie] ; Valentina Grossi [Italie] ; Arianna Damiani [Italie] ; Francesca Li Gobbi [Italie] ; Maristella Piccininni [Italie] ; Gaetano Zaccara [Italie] ; Massimo Cincotta [Italie]	Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
000700 (2019)	Martin Krusche [Allemagne] ; Nikolas Ruffer [Allemagne] ; Ina Kötter [Allemagne]	Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature.
000713 (2019)	Alex Ganetsky [États-Unis] ; Noelle V. Frey [États-Unis] ; Elizabeth O. Hexner [États-Unis] ; Alison W. Loren [États-Unis] ; Saar I. Gill [États-Unis] ; Selina M. Luger [États-Unis] ; James K. Mangan [États-Unis] ; Mary Ellen Martin [États-Unis] ; Daria V. Babushok [États-Unis] ; William R. Drobyski [États-Unis] ; Jacqueline Smith [États-Unis] ; Colleen Timlin [États-Unis] ; Craig W. Freyer [États-Unis] ; Edward A. Stadtmauer [États-Unis] ; David L. Porter [États-Unis]	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
000863 (2019)	Marie Fournier ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Usha G. Mallya [États-Unis] ; Kaleb Michaud [États-Unis]	Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
000898 (2019)	Alexandros A. Drosos ; Eleftherios Pelechas ; Paraskevi V. Voulgari	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
000B11 (2019)	Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] ; Reiji Yamakawa [Japon]	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
000B12 (2019)	Mark C. Genovese [États-Unis] ; Désirée Van Der Heijde [Pays-Bas] ; Yong Lin [États-Unis] ; Gregory St John [États-Unis] ; Sheldon Wang [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Juan José G Mez-Reino [Espagne] ; Alan Kivitz [États-Unis] ; José Antonio Maldonado-Cocco [Argentine] ; Bruno Seriolo [Italie] ; Marina Stanislav [Russie] ; Gerd R. Burmester [Allemagne]	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
000B43 (2019)	Kalpana Babu [Inde] ; Bhagya Sudheer [Inde] ; Anand P. Rao [Inde]	Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema – A case report
000B77 (2019)	Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]	Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
000B86 (2019)	Aroon D. Hingorani [Royaume-Uni] ; Valerie Kuan [Royaume-Uni] ; Chris Finan [Royaume-Uni] ; Felix A. Kruger [Royaume-Uni] ; Anna Gaulton [Royaume-Uni] ; Sandesh Chopade [Royaume-Uni] ; Reecha Sofat [Royaume-Uni] ; Raymond J. Macallister [Royaume-Uni] ; John P. Overington [Royaume-Uni] ; Harry Hemingway [Royaume-Uni] ; Spiros Denaxas [Royaume-Uni] ; David Prieto [Royaume-Uni, Espagne] ; Juan Pablo Casas [États-Unis]	Improving the odds of drug development success through human genomics: modelling study
000C32 (2019)	Peter. C. Taylor [Royaume-Uni] ; Alejandro Balsa Criado ; Anne-Barbara Mongey ; Jerome Avouac ; Hubert Marotte ; Rudiger B. Mueller	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
000C44 (2019)	Vibeke Strand [États-Unis] ; Sophie Dimonaco [Royaume-Uni] ; Katie Tuckwell [États-Unis] ; Micki Klearman [États-Unis] ; Neil Collinson [Royaume-Uni] ; John H. Stone [États-Unis]	Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
000C51 (2019)	Eleftherios Pelechas [Grèce] ; Alexandra Papoudou-Bai [Grèce] ; Paraskevi V. Voulgari [Grèce] ; Alexandros A. Drosos [Grèce]	Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.
000C93 (2019)	Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
000D40 (2019)	Aly M. Abdelrahman [Oman] ; Yousuf Al Suleimani ; Asem Shalaby [Oman] ; Mohammed Ashique ; Priyadarsini Manoj ; Badreldin H. Ali	Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.
000D46 (2019)	Iván Ferraz-Amaro [Espagne] ; María Vanesa Hernández-Hernández [Espagne] ; Beatriz Tejera-Segura [Espagne] ; Esmeralda Delgado-Frías [Espagne] ; María Macía-Díaz [Espagne] ; Jose David Machado [Espagne] ; Federico Diaz-González [Espagne]	Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "every" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "every" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    every
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021